IL17A and colorectal carcinoma: We further co-cultured sorted CD8+ T cells with sera collected from advanced-stage CRC patients and found that the percentage of CXCR3+CD8+ T cells was reduced; this percentage was upregulated after treatment with anti-IL-17A or Stattic (Fig. 4i).